Findings

What do systematic reviews say?

24 questions · 24 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 29.2%GRADE not reported 0 · 0%Very low 1 · 4.2%Low 6 · 25%Moderate 10 · 41.7%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Canakinumab vs triamcinolone acetonide · Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins
  Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
  RR 1.39 [1.11, 1.74]
  3 studies · 523 participants
  Moderate
Direct match · question page
- Canakinumab vs triamcinolone acetonide · Pain: at 72 hours (canakinumab 150 mg)
  Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 443 participants
  Moderate
Direct match · question page
- Canakinumab vs triamcinolone acetonide · Participant global assessment of response to treatment: good or excellent at 72 hours (canakinumab 150 mg) Assessed by the participant on a 5‐point Likert scale (excellent, good, acceptable, slight or poor)
  Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
  RR 1.37 [1.16, 1.61]
  3 studies · 478 participants
  Moderate
Direct match · question page
- Canakinumab vs placebo · Number of participants experiencing an attacka
  Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  RR 0.41 [0.26, 0.65]
  1 study · 63 participants
  Moderate
Direct match · question page
- Canakinumab vs placebo · Acute‐phase response
  Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  Moderate

Canakinumab vs triamcinolone acetonide

Pain: at 72 hours (canakinumab 150 mg) · acute gout

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 443 participants
Moderate

Canakinumab vs triamcinolone acetonide

Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout

Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.39 [1.11, 1.74]
3 studies · 523 participants
Moderate

Canakinumab vs triamcinolone acetonide

Global assessment of treatment success · acute gout

Canakinumab probably leads to higher participant global assessment of response to treatment: good or… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.37 [1.16, 1.61]
3 studies · 478 participants
Moderate

Canakinumab vs triamcinolone acetonide

Withdrawals due to adverse events · acute gout

Canakinumab showed no clear difference in study withdrawals due to AE (all canakinumab doses) compared with triamcinolone acetonide (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.07 [0.16, 7.23]
3 studies · 654 participants
Low

Canakinumab vs triamcinolone acetonide

Risk for at least one adverse event per patient · acute gout

Canakinumab probably leads to higher participants with at least 1 AE (all canakinumab doses) compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.2 [1.05, 1.39]
3 studies · 654 participants
Moderate

Canakinumab vs placebo

Number of participants experiencing an attacka · people with colchicine‐resistant familial Mediterranean fever

Canakinumab probably leads to lower number of participants experiencing an attacka compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
RR 0.41 [0.26, 0.65]
1 study · 63 participants
Moderate

Canakinumab vs placebo

Duration of attacks · people with colchicine‐resistant familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo

Time between attacks · people with colchicine‐resistant familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo

Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo

Adverse drug reactions · people with colchicine‐resistant familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Moderate

Canakinumab vs placebo

Acute‐phase response · people with colchicine‐resistant familial Mediterranean fever

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Moderate

Canakinumab vs placebo or usual care

Clinical improvement D28

Canakinumab showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 1.05 [0.96, 1.14]
2 studies · 499 participants
Moderate

Canakinumab vs placebo or usual care

Clinical improvement D60 or above

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo or usual care

WHO progression score (level 7 or above) D28

Canakinumab showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.72 [0.44, 1.2]
2 studies · 499 participants
Low

Canakinumab vs placebo or usual care

WHO Clinical Progression Score of level 7 or above D60 or above

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo or usual care

All‐cause mortality D28

Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.75 [0.39, 1.42]
2 studies · 499 participants
Low

Canakinumab vs placebo or usual care

All‐cause mortality D60 or more

It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.55 [0.16, 1.91]
1 study · 45 participants
Very low

Canakinumab vs placebo or usual care

Adverse events

Canakinumab showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 1.02 [0.86, 1.21]
1 study · 454 participants
Moderate

Canakinumab vs placebo or usual care

Serious adverse eventsÂ

Canakinumab showed no clear difference in serious adverse eventsÂ compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.8 [0.57, 1.13]
2 studies · 499 participants
Low

Canakinumab vs placebo or usual care

Time to clinical improvement

Canakinumab showed no clear difference in time to clinical improvement compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
HR 1.06 [0.87, 1.29]
1 study · 454 participants
Moderate